Kazuo Yamamoto

P1.101. Treatment Selection and Real-World Outcomes of First-Line ICI-Based Therapy for Unresectable or Recurrent Esophageal Cancer in a Regional Hospital

Abstract Topic Esophageal Cancer: Management of Metastatic Cancer Background Based on pivotal clinical trials, immune checkpoint inhibitors (ICIs) have demonstrated efficacy in patients with unresectable advanced or recurrent esophageal cancer and are now incorporated as standard...